EYPT Financials: EyePoint Inc AI Analysis

Q: What are EyePoint Inc's key financial statements?

According to the latest financial statement (Form-10K), EyePoint Inc has a total asset of $418, Net loss of $-130

Q: What are the key financial ratios for EYPT?

EyePoint Inc's Current ratio is 5.16, has a Net margin is -302.32, sales per share of $0.76.

Q: How is EyePoint Inc's revenue broken down by segment or geography?

EyePoint Inc largest revenue segment is Ophthalmic Products, at a revenue of 43,273,000 in the most earnings release.For geography, United States is the primary market for EyePoint Inc, at a revenue of 42,049,000.

Q: Is EyePoint Inc profitable?

no, according to the latest financial statements, EyePoint Inc has a net loss of $-130

Q: Does EyePoint Inc have any liabilities?

yes, EyePoint Inc has liability of 81

Q: How many outstanding shares for EyePoint Inc?

EyePoint Inc has a total outstanding shares of 68.26

Home

Stock

EYPT

EYPT Financial

EyePoint Inc

$15.08

-4.79%

$-0.75

At close: Jan 16, 16:00:00 GMT-5

$15

-0.53%

$-0.08

Post-market: Jan 16, 20:00:00 GMT-5

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$15.84

Open

$15.95

Day's Range

$15 - $16.18

52 week range

$3.91 - $19.11

Volume

869.1K

Avg.Volume

1.2M

EPS (TTM)

-2.99

Dividend yield

Market Cap

$1.2B

What is EYPT?

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 165 full-time employees. The company went IPO on 2005-01-27. The firm is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.



Features

AI Copilot for Stock & Crypto

Trading Strategies

Megabrain Investors Picks

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

EYPT Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	42	43	46	41	36	34
Revenue Growth (YoY)	-7%	-7%	12%	14%	6%	70%
Cost of Revenue	2	3	4	8	8	5
Gross Profit	39	39	41	33	28	28
Selling, General & Admin	56	55	51	60	53	45
Research & Development	201	130	64	49	28	17
Operating Expenses	258	185	116	112	84	65
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-205	-130	-70	-102	-58	-45
Income Tax Expense	0	0	0	--	--	--
Net Income	-205	-130	-70	-102	-58	-45
Net Income Growth	99%	86%	-31%	76%	28.99%	-20%
Shares Outstanding (Diluted)	70.16	56.29	38.9	37.32	28.76	12.84
Shares Change (YoY)	28.99%	45%	4%	30%	124%	23%
EPS (Diluted)	-2.93	-2.32	-1.81	-2.74	-2.03	-3.54
EPS Growth	54%	28%	-34%	35%	-43%	-35%
Free Cash Flow	-213	-130	-1	-67	-50	-14
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	92.85%	90.69%	89.13%	80.48%	77.77%	82.35%
Operating Margin	-519.04%	-337.2%	-163.04%	-190.24%	-152.77%	-105.88%
Profit Margin	-488.09%	-302.32%	-152.17%	-248.78%	-161.11%	-132.35%
Free Cash Flow Margin	-507.14%	-302.32%	-2.17%	-163.41%	-138.88%	-41.17%
EBITDA	-216	-144	-75	-76	-53	-34
EBITDA Margin	-514.28%	-334.88%	-163.04%	-185.36%	-147.22%	-100%
D&A For EBITDA	2	1	0	2	2	2
EBIT	-218	-145	-75	-78	-55	-36
EBIT Margin	-519.04%	-337.2%	-163.04%	-190.24%	-152.77%	-105.88%
Effective Tax Rate	0%	0%	0%	--	--	--

Follow-Up Questions

What are EyePoint Inc's key financial statements?



What are the key financial ratios for EYPT?



How is EyePoint Inc's revenue broken down by segment or geography?



Is EyePoint Inc profitable?



Does EyePoint Inc have any liabilities?



How many outstanding shares for EyePoint Inc?



EyePoint Inc (EYPT) Price

EYPT Stock Price Chart